Skip to main content

Table 4 Progression free survival

From: Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

  ----------Time to PD or Death (days)a----------
  Median (95% CI), days
Overall PFS (N = 74) b 92.0 (79.0, 126.0)
Exploratory Analyses  
PFS by:  
M classification  
   M1a (n = 7) 85.0 (40.0, 270.0)
   M1b (n = 13) 135.0 (103.0, 205.0)
   M1c (n = 54) 85.0 (68.0, 110.0)
Prior chemotherapy  
   With (n = 40) 89.0 (78.0, 143.0)
   Without (n = 34) 97.0 (42.0, 180.0)
Dose escalation of talabostat  
   With (n = 44) 135.0 (89.0, 170.0)
   Without (n = 30) 79.0 (42.0, 109.0)
Initial cisplatin dose  
   100 mg/m2 (n = 35) 80.0 (44.0, 103.0)
   75 mg/m2 (n = 39) 126.0 (85.0, 169.0)
  1. PD = progressive disease; PFS = progression-free survival; CI = confidence interval
  2. a Response is based on the investigator's assessment.
  3. b ITT population.